Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant

Click to increase image sizeClick to decrease image size

Ethics statement

This study was carried out in accordance with the recommendations of the Ethics Committee of the First affiliated Hospital of Soochow University. All protocols conformed to the guidelines of the Ethics Committee of the First affiliated Hospital of Soochow University and the Declaration of Helsinki.

Author contributions

SJ, YQC, JJS, and YYZ: contribution of patients, acquisition of data, analysis and interpretation of data. SJ, CCF, MM, and ANS: design of study, acquisition of funding contribution of patients, interpretation of data, supervision of the study, and revision of the manuscript. QYW, LZY, XLS, JW, YY, and HFZ: contribution of patients and revision of the manuscript. YQC, JJS, and YYZ wrote the paper. All authors read and approved the final manuscript.

Consent form

The patient gave informed consent in accordance with the Declaration of Helsinki. Patient consent was obtained, for publication of a case report with images.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

For original data, please contact Song Jin.

Additional information

Funding

This work was supported by National Natural Science Foundation of China (81100342, 82270210, 81873432, 82070143, and 82000181), Grants from the Jiangsu Province of China (BE2021645), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).